EP Patent

EP3714888A1 — Compounds for use in the treatment of adcy5-related dyskinesia

Assigned to Assistance Publique Hopitaux de Paris APHP · Expires 2020-09-30 · 6y expired

What this patent protects

The present invention relates to compounds of formula (I), preferably caffeine, and compositions comprising said compounds, for use in the treatment ofADCY5-related dyskinesia.

USPTO Abstract

The present invention relates to compounds of formula (I), preferably caffeine, and compositions comprising said compounds, for use in the treatment ofADCY5-related dyskinesia.

Drugs covered by this patent

Patent Metadata

Patent number
EP3714888A1
Jurisdiction
EP
Classification
—
Expires
2020-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Assistance Publique Hopitaux de Paris APHP
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.